ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02648711 (Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies
Who cites it
17 citing papers in PubMed, 52 citations in OpenAlex.
- Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.Journal of pharmaceutical and biomedical analysis · 2020Trial
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.Investigational new drugs · 2013Trial
- Cancer nanotechnology: current status and perspectives.Nano convergence · 2021Review
- Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers.Journal of biomedical science · 2019Article
- Cancer-targeted design of bioresponsive prodrug with enhanced cellular uptake to achieve precise cancer therapy.Drug delivery · 2018Article
- Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?American journal of cancer research · 2017Review
- Article
- Clinical Translation of Nanomedicine.Chemical reviews · 2015Review
- The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.BMC cancer · 2014Article
- Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Disulfide cross-linked phosphorylcholine micelles for triggered release of camptothecin.Molecular pharmaceutics · 2013Article
- Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.Journal of drug delivery · 2012Article
- CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.Current bioactive compounds · 2011Article
- Clinical developments in nanotechnology for cancer therapy.Pharmaceutical research · 2011Review
- Host-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene delivery.ACS nano · 2010Article
- Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
purposeCamptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. EXPERIMENTAL
designWe determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated.
resultsIT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice.
conclusionsThe promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.